We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+22.13%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$282M
AUM Growth
+$20.8M
Cap. Flow
-$2.51M
Cap. Flow %
-0.89%
Top 10 Hldgs %
98.41%
Holding
16
New
–
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
MRKR icon
Marker Therapeutics
MRKR
+$39.3K

Top Sells

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$2.55M
2
OKUR
OnKure Therapeutics
OKUR
+$15

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$167M 59.08%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$51.8M 18.38%
1,115,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$13.6M 4.81%
1,025,000
– –
GLUE icon
4
Monte Rosa Therapeutics
GLUE
$1.4B
$10.2M 3.63%
1,472,331
– –
PSTX
5
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10M 3.55%
1,043,267
– –
BCAX
6
Bicara Therapeutics
BCAX
$1.78B
$9.91M 3.52%
568,919
– –
NUVB icon
7
Nuvation Bio
NUVB
$2.2B
$6.76M 2.4%
2,541,009
– –
CMPS
8
Compass Pathways
CMPS
$1.53B
$3.65M 1.29%
964,500
– –
BMEA icon
9
Biomea Fusion
BMEA
$84.6M
$3.1M 1.1%
798,757
– –
CALC icon
10
CalciMedica
CALC
$15.8M
$1.84M 0.65%
521,114
– –
ELEV
11
DELISTED
Elevation Oncology
ELEV
$1.59M 0.56%
2,834,910
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$726M
$1.08M 0.38%
434,455
– –
MRKR icon
13
Marker Therapeutics
MRKR
$18.8M
$1.01M 0.36%
325,370
+11,084
+4% +$39.3K
OKUR
14
OnKure Therapeutics
OKUR
$154M
$762K 0.27%
88,607
-1
-0% -$15
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$46.2K 0.02%
288,571
– –
TECX
16
Tectonic Therapeutic
TECX
$529M
– –
-84,148
Closed -$2.55M

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Aisling Capital Management held 16 positions worth $282M, up 8% from $261M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aisling Capital Management's Q4 2024 filing shows 1 increased, 1 reduced and 1 closed positions. The largest sale was Tectonic Therapeutic, an estimated $2.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management added most to Marker Therapeutics in Q4 2024, an estimated $39.3K increase.
  • Aisling Capital Management's biggest Q4 2024 reduction was OnKure Therapeutics, cutting an estimated $15.
  • Aisling Capital Management fully exited Tectonic Therapeutic in Q4 2024, selling an estimated $2.55M.
  • Aisling Capital Management's ten largest holdings make up 98% of its $282M portfolio in Q4 2024.
  • Aisling Capital Management opened 0 new positions and closed 1 in Q4 2024.
  • Aisling Capital Management's portfolio value rose 8% quarter-over-quarter to $282M.

Based on Aisling Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.